CTRI/2020/02/023101尚未招募3 期
A phase III, two arm, multicentric, randomized, open label, parallel, multiple dose pharmacodynamics study of Goserelin 3.6 mg Injection (Eurofarma Laboratorios S. A.) administered subcutaneously in comparison with the reference drug ZOLADEX® 3.6 mg Injection (AstraZeneca) administered subcutaneously in premenopausal patients with advanced Breast cancer.
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Pre-menopausal female patients of 18 to 50 years of age (both inclusive).
- •2. BMI 18.5 to 30 kg/m2 (both inclusive).
- •3. Patient with a confirmed diagnosis of advanced breast cancer (TNM stage III or
- •stage IV or recurrent metastatic disease) who are scheduled to start goserelin
- •therapy as per Investigator discretion.
- •4. Hormone sensitivity (ER positive) of primary or secondary tumour tissue
- •5. Patients with baseline estradiol levels >30 pg/mL
- •6. Patients must be able to understand the investigational nature of this study and to give written informed consent prior to the participation in the trial.
- •7. Eastern Cooperative Oncology Group (ECOG) performance status <= 2.
- •8. Patients with life expectancy of at least 3 months as judged by the Investigator.
- •9. Patient should have recovered from any toxic effects of previous
- •chemotherapy as judged by the Investigator.
- •10. Patient should be able to comply with study requirement in the opinion of Investigator.
- •11. Non-smoker defined as non-smoker for at least 6 months (i.e. subject has not smoked or used any tobacco products for the 6 months prior to the screening visit).
- •12. Patients must not have taken any anti-androgens, estrogen, antiestrogen, selective estrogen receptor modulators, aromatase inhibitors or hormonal forms of contraception within past one month of screening. Patient may have had recent use of oral contraceptive pills but these must be discontinued 30 days prior to dosing.
- •13. Adequate hematologic status, renal and liver function.
- •14. Women of childbearing potential must not be pregnant or breastfeeding (as documented by a negative serum pregnancy test at screening
- •and negative urine pregnancy test at baseline).
- •15. Women of childbearing potential or her partner must use an acceptable and effective non-hormonal method of avoiding pregnancy,
- •starting at least four weeks before the study drug administration and up to 12 weeks after the after the last dose of study drug administration. Cessation of birth control after this point should be discussed with the responsible physician. For this study, acceptable and effective methods of contraception include:
- •a) Tubal sterilization (tubal ligation performed more than one month before Study Day 1; transcervical tubal occlusion procedure performed more than six months before Study Day 1)
- •b) Barrier method (cervical cap, diaphragm, contraceptive sponge, vaginal spermicide, female condom, or male condom)
- •c) Two barrier methods used together (cervical cap, diaphragm, contraceptive sponge, or vaginal spermicide plus a male or female condom)
- •d) Absolute sexual abstinence (no sexual intercourse or genital contact with a
- •male partner). If the patient becomes sexually active during the study, then she is required to use a double barrier method of contraception.
排除标准
- •1. Patients who are not able to provide written informed consent.
- •2. Patients who are menopausal.
- •3. Patients who are scheduled to receive any chemotherapy/radiotherapy in addition to goserelin.
- •4. Patients who are already on GnRH receptor agonist or antagonist therapy.
- •5. Patients who have previously failed on GnRH receptor agonist or antagonist therapy.
- •6. Presence of life-threatening metastatic visceral disease, defined as extensive hepatic involvement, or any degree (proven or suspected) of brain or leptomeningeal involvement (past or present) or symptomatic pulmonary lymphangitic spread. Patients with discrete pulmonary parenchymal metastases
- •are eligible, provided their respiratory function is not compromised as a result of the disease.
- •7. Patients who are intended to be started on any medication apart from study drug that can have impact on any of the study endpoints.
- •8. Patients who are pregnant or breastfeeding.
- •9. Concurrent malignancy or history of malignancy (apart from disease condition
- •under study) within last 5 years before screening except curatively treated carcinoma in situ of the uterine cervix or basal cell carcinoma of the skin
- •10. Patients with a clinically significant medical condition other than advanced breast cancer including but not limited to renal, hepatic, gastrointestinal, endocrine, cardiovascular, neurological or psychiatric disease, alcohol or substance abuse, or any other condition that may affect the patient health or the outcome of the trial as judged by the investigator.
- •11. Presence of clinically significant physical exam, laboratory, medical history, ECG/echocardiogram findings that in the opinion of the Investigator may interfere with trial conduct, patient safety, or interpretation of results.
- •12. Patients with a known hypersensitivity to GnRH, GnRH-agonist analogues or any of the components in IMP.
- •13. Patients receiving anticoagulation medications.
- •14. Patients with uncontrolled diabetes mellitus (HbA1c > 8 % as per ADA) at randomization (those who have controlled blood sugar (fasting) will be eligible for randomization)
- •15. Patients with confirmed signs or symptoms related to cerebral metastasis or radiographically confirmed brain metastasis.
- •16. Uncontrolled hypertension (systolic blood pressure [BP] >140 or diastolic BP >90mm Hg) or uncontrolled cardiac arrhythmias. (Patients with hypertension controlled by antihypertensive therapies are eligible).
- •17. Patients with a QTc >450ms on the ECG at screening.
- •18. History of clinically significant cardiovascular disorder
- •19. Use of any recreational drugs (cocaine, amphetamines, barbiturates, benzodiazepines, cannabinoids and morphine) or history of drug or alcohol abuse within the past 1 year, as judged by the Investigator, or a positive result on the urine drug/alcohol screen which is not consistent with current medical treatment.
- •20. Concomitant use of medicinal products known to prolong the QT interval or
- •medicinal products able to induce Torsade de pointes such as class IA (e.g. quinidine, disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin,
- •antipsychotics.
- •21. A positive hepatitis screen including hepatitis B surface antigen or HCV antibodies.
- •22. Patients who test positive for HIV and
研究者
相似试验
尚未招募
3 期
A study of Goserelin 10.8 mg Injection in comparison with the drug ZOLADEX® 10.8 mg Injection in patients with prostate cancer.CTRI/2020/02/023211Eurofarma Laboratrios SA
已完成
3 期
A clinical trial to study safety and efficacy of Bepotastine besilate in patient with allergic rhinitis.CTRI/2015/10/006262upin Limited India240
进行中（未招募）
不适用
A phase III, randomized, double blind, multicenter, parallel group, placebo and active controlled, dose optimization safety and efficacy study of Lisdexamfetamine Dimesylate (LDX) in children and adolescent aged 6-17 with attention-deficit/hyperactivity disorder (ADHD)Attention Deficit/Hyperactivity Disorder ADHDMedDRA version: 14.1Level: LLTClassification code 10064104Term: ADHDSystem Organ Class: 100000004873EUCTR2008-000679-90-ITShire Pharmaceutical Development Limited300
招募中
3 期
The comparison of the efficacy and safety between Temziva and Actemra in treatment of the patient with active Rheumatoid ArthritisRheumatoid Arthritis.Other seropositive rheumatoid arthritis ,Seronegative rheumatoid arthritisM05.8, M06IRCT20150303021315N9AryoGen Pharmed Co.272
进行中（未招募）
1 期
Study aiming at proving the efficacy, safety and tolerability of inhaled Itraconazole in the prevention of Invasive Mould Disease (infections of the lungs by fungi) in patients with Acute Leukaemia and Neutropaenia (abnormally low concentration of neutrophils in the blood)prevention of invasive mould diseaseMedDRA version: 20.0Level: LLTClassification code 10003488Term: AspergillosisSystem Organ Class: 100000004862EUCTR2019-002408-42-PLABORATOIRES SMB S.A.462